ERBB2 and breast carcinoma: Our findings in the first-line THP setting further support the prognostic value of HER2DX ERBB2 mRNA score, indicating that ERBB2 mRNA is a robust biomarker across multiple lines of therapy in metastatic HER2+ breast cancer.